Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes
- Genetic variation in a particular chromosome is a major contributor to the increased risk for kidney disease that is common in people of African descent, although the specific gene, mutations, and other aspects of the variations remain to be determined. By studying the outcomes of kidney transplant in donors and recipients of African descent, researchers hope to better understand the effects of this genetic variation on the success of kidney transplants.
- To examine possible connections between genetic variations and kidney transplant outcomes for donors and recipients.
- < TAB> Participants in kidney transplant where both donor and recipient were of black African descent.
- < TAB> Eligible transplants include both living donor and deceased donor.
- The study will involve one visit of up to 8 hours.
- All participants will provide a detailed personal and family medical history.
- All participants will provide blood and urine samples, including a 24-hour urine collection, to test kidney function and collect material for genetic testing.
- Donor participants will also have a magnetic resonance imaging (MRI) scan of their remaining kidney.
Kidney Failure, Chronic
|Study Design:||Time Perspective: Retrospective|
|Official Title:||Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes|
|Study Start Date:||May 2010|
Genetic variation in the region of MYH9, encoding non-muscle myosin IIA heavy chain, located on chromosome 22, is a major contributor to the increased risk for kidney disease that characterizes African descent populations, although the specific gene, causative mutations, and the molecular and cellular mechanisms remain to be determined. We propose to study the role of MYH9 region genetic variation, as well as other genes, in renal transplant, including the effect of donor genotype on recipient outcomes and on donor outcomes. Additional exploratory studies will address 1) whether variation in other donor genes might contribute to donor and recipient outcomes, which we may address with candidate gene studies or a genome-wide association study and 2) whether recipient genotype contributes to recipient outcomes, which we will address in similar ways. In separate but related studies, we will work with various collaborators who pursuing similar question under research protocols that they have generated and for which they have local IRB approvals. We will receive from these collaborators materials for preparation of DNA, from which we will genotype APOL1 and other genes known or hypothesized to be related to donor and recipient transplant outcomes
Please refer to this study by its ClinicalTrials.gov identifier: NCT01143532
|Contact: Cheryl Winkler, Ph.D.||(301) email@example.com|
|Contact: Jeffrey B Kopp, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|University of Maryland, Baltimore||Recruiting|
|Baltimore, Maryland, United States, 21201-1595|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Walter Reed National Medical Center||Recruiting|
|Bethesda, Maryland, United States, 20301|
|United States, Michigan|
|University of Michigan||Recruiting|
|Ann Arbor, Michigan, United States, 48109-0624|
|Henry Ford Health Systems||Recruiting|
|Detroit, Michigan, United States, 48202|
|Wayne State University Hutzel Hospital||Recruiting|
|Detroit, Michigan, United States, 48201|
|Principal Investigator:||Jeffrey B Kopp, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|